- Home
- URGN vs BKN Comparison
URGN vs BKN Comparison
Compare URGN & BKN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- BKN
- Stock Information
- Founded
- URGN 2004
- BKN 1992
- Country
- URGN United States
- BKN United States
- Employees
- URGN N/A
- BKN N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- BKN Trusts Except Educational Religious and Charitable
- Sector
- URGN Health Care
- BKN Finance
- Exchange
- URGN Nasdaq
- BKN Nasdaq
- Market Cap
- URGN 831.6M
- BKN 180.8M
- IPO Year
- URGN 2017
- BKN N/A
- Fundamental
- Price
- URGN $18.90
- BKN $10.56
- Analyst Decision
- URGN Strong Buy
- BKN
- Analyst Count
- URGN 8
- BKN 0
- Target Price
- URGN $29.00
- BKN N/A
- AVG Volume (30 Days)
- URGN 1.3M
- BKN 55.5K
- Earning Date
- URGN 08-07-2025
- BKN 01-01-0001
- Dividend Yield
- URGN N/A
- BKN 4.38%
- EPS Growth
- URGN N/A
- BKN N/A
- EPS
- URGN N/A
- BKN N/A
- Revenue
- URGN $91,871,000.00
- BKN N/A
- Revenue This Year
- URGN $39.80
- BKN N/A
- Revenue Next Year
- URGN $108.94
- BKN N/A
- P/E Ratio
- URGN N/A
- BKN N/A
- Revenue Growth
- URGN 8.98
- BKN N/A
- 52 Week Low
- URGN $3.42
- BKN $9.57
- 52 Week High
- URGN $19.36
- BKN $12.69
- Technical
- Relative Strength Index (RSI)
- URGN 75.30
- BKN 35.49
- Support Level
- URGN $17.68
- BKN $10.46
- Resistance Level
- URGN $19.36
- BKN $10.66
- Average True Range (ATR)
- URGN 1.05
- BKN 0.09
- MACD
- URGN 0.27
- BKN -0.03
- Stochastic Oscillator
- URGN 92.16
- BKN 20.41
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About BKN BlackRock Investment Quality Municipal Trust Inc. (The)
Blackrock Investment Quality Municipal Trust, Inc. is a closed-end management investment fund with the investment objective to provide high current income exempt from regular U.S. federal income tax consistent with the preservation of capital.